168635-85-6
Chemical Structure
Carcinoembryonic antigen peptide 1
Synonym(s): CEA peptide
- CAS No.: 168635-85-6
- Formula:C43H69N11O14
- Molecular Weight:964.07
IUPAC Name: L-tyrosyl-L-leucyl-L-serylglycyl-L-alanyl-L-asparaginyl-L-leucyl-L-asparaginyl-L-leucine
InChIKey: JHESAKNQFPFWLN-UOGODTEOSA-N
SMILES: O=C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC1=CC=C(C=C1)O)N
Biological Activity: Carcinoembryonic antigen peptide 1 (CEA peptide) is a 9-amino acid HLA-A0201-binding cytotoxic T lymphocyte (CTL) epitope peptide derived from carcinoembryonic antigen (CEA). The IC50 of Carcinoembryonic antigen peptide 1 binding to HLA-A0201 is 2 μM. Carcinoembryonic antigen peptide 1 binds to HLA-A0201 to form a peptide-MHC I complex, which is recognized by the T cell receptor (TCR) of CAP1-specific CD8+ CTLs, thereby inducing antigen-specific T cell activation, IFN-γ production, and CTL-mediated lysis of target cells. Carcinoembryonic antigen peptide 1 is used in research on CEA-specific CTL responses and colorectal cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carcinoembryonic antigen peptide 1 | 99.69% | Carcinoembryonic antigen peptide 1 (CEA peptide) is a 9-amino acid HLA-A0201-binding cytotoxic T lymphocyte (CTL) epitope peptide derived from carcinoembryonic antigen (CEA). The IC50 of Carcinoembryonic antigen peptide 1 binding to HLA-A0201 is 2 μM. Carcinoembryonic antigen peptide 1 binds to HLA-A0201 to form a peptide-MHC I complex, which is recognized by the T cell receptor (TCR) of CAP1-specific CD8+ CTLs, thereby inducing antigen-specific T cell activation, IFN-γ production, and CTL-mediated lysis of target cells. Carcinoembryonic antigen peptide 1 is used in research on CEA-specific CTL responses and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fauquembergue E, et al. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010 May;33(4):402-13.
- [2]. Wang B, et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood. 2004 Jul 01;104(1):200-6.
- [3]. Ras E, et al. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Human immunology. 1997 Mar;53(1):81-9. [Content Brief]
- [4]. Zaremba S, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer research. 1997 Oct 15;57(20):4570-7. [Content Brief]
